OmniAb : Submission of Matters to a Vote of Security Holders Form 8 K
June 21, 2024 at 06:03 am EDT
Share
Item 5.07. Submission of Matters to a Vote of Security Holders.
OmniAb, Inc. (the "Company") held its 2024 Annual Meeting of Shareholders (the "Annual Meeting") on June 18, 2024. Set forth below are the final voting results for the actions taken by the shareholders at the Annual Meeting.
Proposal 1.The election of two directors to serve as Class II directors for a three-year term to expire at the 2027 Annual Meeting of Shareholders. The following two Class II directors were elected by the votes indicated:
For
Withheld
Broker Non-Votes
Sarah Boyce
61,512,919
19,906,776
14,109,982
Steve Love
80,325,457
1,094,238
14,109,982
Proposal 2.The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The appointment was ratified by the votes indicated:
For
Against
Abstain
Broker Non-Votes
93,272,240
2,195,483
61,954
0
Attachments
Original Link
Permalink
Disclaimer
OmniAb Inc. published this content on
21 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
21 June 2024 10:02:08 UTC.
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
OMNIAB, INC. 
